Your Cart

About Us

We’re on a mission to make cancer more detectable.

Early detection saves lives.

We’re developing next-generation molecular imaging technologies that find cancer and other diseases using bio-safe magnetic nanoparticles.

Treatments are more successful and survival rates improve with early detection.

By combining high-sensitivity imaging technologies with nanoparticle technology, we aim to make the detection of diseases like cancer better and safer for patients as well as provide new methods for therapeutic intervention.

Play Video

Recent Milestones

Feb 2023

Updated strategy to develop the MagSense® nanoparticle technology for use with clinical MRI systems.

Feb 2023

Independent review by radiologists confirmed the MagSense® HER2 Imaging Agent produces a unique and differentiable image contrast in lymph nodes suspicious for tumor. This unique molecular signature is critical to discriminate lymph nodes with tumor cells from normal nodes and has the potential to improve nodal assessment for staging over current methods.

Dec 2022

Presented interim data from MagSense® HER2 Breast Cancer Phase I study at the San Antonio Breast Cancer Symposium showing imaging agent showed no safety findings of significance and reaches its target tissue (axillary lymph nodes) with the planned route of administration and shows unique and differentiable MR contrast pattern in nodes suspicious for tumor.

Sept 2022

Presented prostate cancer research data at the World Molecular Imaging Congress with MagSense® imaging agent showing high specificity and selectivity

Apr 2022

Sponsored Research Agreement executed with researchers at Massachusetts General Hospital focuses on MRI 

Mar 2022

MagSense® HER2 Breast Cancer Phase I study interim results indicate imaging agent is well-tolerated and is reaching patient’s lymph nodes

Aug 2021

Joint Development Agreement with Global Cancer Technologies to develop nanocrystals for treatment of breast cancer

May 2021

Collaboration with Patrys (ASX:PAB) for Brain Cancer imaging

May 2021

First patient dosed in Phase I study

Mar 2021

Receive CSIRO grant to support Prostate Cancer imaging research

Mar 2020

MagSense® HER2 Breast Cancer Phase I study opens for enrolment

Oct 2020

HREC approval for MagSense® HER2 Breast Cancer Phase I study in Australia

May 2020

Research collaboration with Siemens

Jul 2019

Received FDA designation as a ”Breakthrough Device”

Why you should use our PrecisionMRX® magnetic nanoparticles for your biomedical application

We have developed a proprietary method for making magnetic nanoparticles that precisely controls for key attributes, such as size, dispersity, and magnetic properties, important in biomedical application.

There are three biomedical applications of our magnetic nanoparticles.

About Imagion Biosystems

Research & Imaging

We sell our PrecisionMRX® nanoparticles to institutions for research purposes.

Multiple coating types available.

About Imagion Biosystems

Whitelabeled OEM Products

We supply nanoparticles that can be used in third-party branded products across hyperthermia, human and animal vaccines, and cancer screening and treatments.

Imagion Biosystems

Diagnostic Imaging

MagSense® imaging agents can be developed for many types of solid tumors and can be used at multiple stages of diagnosis including primary diagnosis, staging, and prognosis of diseases.

World class scientific collaborations & partnerships

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.